Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 May 4;90(9):1715-9.
doi: 10.1038/sj.bjc.6601796.

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract

C Hsu  1 , Y-C Shen, C-H Yang, K-H Yeh, Y-S Lu, C-H Hsu, H-T Liu, C-C Li, J-S Chen, C-Y Wu, A-L Cheng
Affiliations
Clinical Trial

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract

C Hsu et al. Br J Cancer. .

Abstract

Both gemcitabine and weekly 24-h infusion of high-dose 5-fluorouracil/leucovorin (HDFL) have shown promising antitumour activity for patients with locally advanced or metastatic carcinoma of the biliary tract (CBT). From April 1999 through December 2002, 30 patients with inoperable CBT were treated with gemcitabine 800 mg m(-2), intravenous infusion for 30 min, followed by 5-FU, 2000 mg m(-2) and leucovorin, 300 mg m(-2), intravenous infusion for 24 h, on day 1, 8 and 15, every 4 weeks. A total of 166 cycles were given (median of four cycles per patient, range 1-24 cycles). Response was evaluable in 28 patients and toxicity in 29 patients. Partial response was obtained in six patients, stable disease in 13, while progressive disease occurred in nine. The objective response rate was 21.4% (95% CI: 5.2-37.6%). The most common grade 3 or 4 toxicity was infection (nine patients). Other types of grade 3 or 4 toxicity included leucopenia (four patients), thrombocytopenia (three patients), anaemia (three patients), nausea/vomiting (two patients) and elevation of liver transaminases (three patients). As of 30 September 2003, the median progression-free survival was 3.7 months (95% CI: 2.8-4.6 months) and the median overall survival was 4.7 months (95% CI: 0.8-8.6 months). Our data suggest that weekly gemcitabine plus HDFL is modestly active with acceptable treatment-related toxicity for patients with advanced CBT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The overall and progression-free survival curves of the patients.
See this image and copyright information in PMC

References

    1. Andre T, Louvet C, Amu P, Selle F, Tournigand C, Garcia ML, Avenin D, Maindraults F, Provent S, de Gramont A (2001) A phase II study of gemcitabine and oxaliplatln (gemox) in advanced blliary adenocarcinoma (ABA). Preliminary results. Eur J Cancer 37(Suppl 6): 19 (abstrct A60)
    1. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L (1991) A phase II study of weekly 24-h infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625–630 - PubMed
    1. Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvement is survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413 - PubMed
    1. Carraro S, Servienti PJ, Bruno MF, Odena M, Roca E, Jovtis S, Felci N, Araujo C (2001) Gemcitabine and cisplatin in locally advanced or metastatic gallbladder and bile duct adenocarcinomas. Proc Am Soc Clin Oncol 20: 2333 (abstract)
    1. de Gramont A, Louvet C, Andre T, Tournigand C, Krulik M (1998) A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 34: 619–626 - PubMed

Publication types

MeSH terms